Original Research January 29, 2024

Telehealth Collaborative Care Led by Clinical Pharmacists for People With Psychosis or Bipolar Disorder: A Propensity Weighted Comparison With Usual Psychiatric Care

Esti Iturralde, PhD; Lisa Fazzolari, DO; Natalie E. Slama, MPH; Stacey E. Alexeeff, PhD; Stacy A. Sterling, MSW, DrPH; Sameer Awsare, MD; Maria T. Koshy, MD; Macy Shia, PharmD

J Clin Psychiatry 2024;85(1):23m14917

ABSTRACT

Objective: People with psychosis or bipolar disorder (severe and persistent mental illness [SPMI]) are at high risk for poor psychiatric and chronic illness outcomes, which could be ameliorated through improved health care quality. This study assessed whether a telehealth, collaborative care program managed by psychiatric clinical pharmacists (SPMI Population Care) was associated with improved health care quality for adults with SPMI in a large California health system.

Methods: This retrospective cohort study used electronic health record data to compare 968 program enrollees at 6 demonstration sites (Population Care) to 8,339 contemporaneous patients with SPMI at 6 non-program sites (Usual Care). SPMI diagnoses were based on ICD-10-CM diagnostic codes. Primary outcomes were optimal psychotropic medication adherence, guideline-recommended glycemic screening, annual psychiatrist visit, and emergency department use. Difference-in-difference analyses assessed change in outcomes from 12 months pre- to 12 months post-enrollment using overlap weighting with high dimensional propensity scores to balance participant characteristics across groups. Participant data were collected from January 1, 2020, to June 30, 2022.

Results: From pre- to post-enrollment, Population Care was associated with greater achievement of psychotropic medication adherence and glycemic screening (+6 and +9 percentage points), but unexpectedly with a decrease in annual psychiatrist visits (−6 percentage points) and no significant change in emergency department use, relative to Usual Care. More than 75% of Population Care participants attended an intake and ≥ 1 follow-up visits. Participants with psychosis (26% of sample) had similar results as those with bipolar disorder.

Conclusions: Clinical pharmacist–led telehealth collaborative care has potential to improve psychopharmacologic treatment adherence and recommended disease preventive screening for people with psychosis or bipolar disorder.

J Clin Psychiatry 2024;85(1):23m14917

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195–1203. PubMed CrossRef
  2. Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–251. PubMed CrossRef
  3. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders, I: prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52–77. PubMed CrossRef
  4. Wade M, Tai S, Awenat Y, et al. A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis. Clin Psychol Rev. 2017;51:75–95. PubMed CrossRef
  5. Kreyenbuhl J, Nossel IR, Dixon LB. Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: a review of the literature. Schizophr Bull. 2009;35(4):696–703. PubMed CrossRef
  6. Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–218. PubMed CrossRef
  7. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334–341. PubMed CrossRef
  8. Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172–1181. PubMed CrossRef
  9. Iturralde E, Slama N, Kline-Simon AH, et al. Premature mortality associated with severe mental illness or substance use disorder in an integrated health care system. Gen Hosp Psychiatry. 2021;68:1–6. PubMed CrossRef
  10. Perkins R, Rinaldi M. Unemployment rates among patients with long-term mental health problems: a decade of rising unemployment. Psychiatr Bull. 2002;26(8):295–298. CrossRef
  11. Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119–136. PubMed CrossRef
  12. Chwastiak LA, Rosenheck RA, Kazis LE. Association of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans. Psychosomatics. 2011;52(3):230–236. PubMed CrossRef
  13. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601. PubMed CrossRef
  14. Mangurian C, Schillinger D, Newcomer JW, et al. Diabetes screening among antipsychotic-treated adults with severe mental illness in an integrated delivery system: a retrospective cohort study. J Gen Intern Med. 2018;33(1):79–86. PubMed CrossRef
  15. Melamed OC, Wong EN, LaChance LR, et al. Interventions to improve metabolic risk screening among adult patients taking antipsychotic medication: a systematic review. Psychiatr Serv. 2019;70(12):1138–1156. PubMed CrossRef
  16. Solmi M, Fiedorowicz J, Poddighe L, et al. Disparities in screening and treatment of cardiovascular diseases in patients with mental disorders across the world: systematic review and meta-analysis of 47 observational studies. Am J Psychiatry. 2021;178(9):793–803. PubMed CrossRef
  17. Hsueh L, Iturralde E, Slama NE, et al. Cardiometabolic monitoring and sociodemographic and clinical characteristics of youths prescribed antipsychotic medications. Psychiatr Serv. 2023;74(8):801–808. PubMed CrossRef
  18. New American Economy. The silent shortage: how immigration can address the large and growing psychiatrist shortage in the United States. 2017. Accessed February 7, 2022. http://www.newamericaneconomy.org/wp-content/uploads/2017/10/NAE_PsychiatristShortage_V6-1.pdf
  19. Institute of Medicine. Improving the Quality of Health Care for Mental and Substance-Use Conditions. National Academy Press; 2006.
  20. Totura CMW, Fields SA, Karver MS. The role of the therapeutic relationship in psychopharmacological treatment outcomes: a meta-analytic review. Psychiatr Serv. 2018;69(1):41–47. PubMed CrossRef
  21. Druss BG, von Esenwein SA, Compton MT, et al. A randomized trial of medical care management for community mental health settings: the Primary Care Access, Referral, and Evaluation (PCARE) study. Am J Psychiatry. 2010;167(2):151–159. PubMed CrossRef
  22. Jones S, Howard L, Thornicroft G. “Diagnostic overshadowing”: worse physical health care for people with mental illness. Acta Psychiatr Scand. 2008;118(3):169–171. PubMed CrossRef
  23. Thornicroft G, Rose D, Kassam A. Discrimination in health care against people with mental illness. Int Rev Psychiatry. 2007;19(2):113–122. PubMed CrossRef
  24. Kisely S, Campbell LA, Wang Y. Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare. Br J Psychiatry. 2009;195(6):545–550. PubMed CrossRef
  25. Katon WJ, Seelig M. Population-based care of depression: team care approaches to improving outcomes. J Occup Environ Med. 2008;50(4):459–467. PubMed CrossRef
  26. Gilbody S, Bower P, Fletcher J, et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med. 2006;166(21):2314–2321. PubMed CrossRef
  27. Panagioti M, Bower P, Kontopantelis E, et al. Association between chronic physical conditions and the effectiveness of collaborative care for depression: an individual participant data meta-analysis. JAMA Psychiatry. 2016;73(9):978–989. PubMed CrossRef
  28. Coleman KJ, Dreskin M, Hackett DL, et al. A roadmap for institutionalizing collaborative care for depression in a large integrated healthcare system. J Gen Intern Med. 2020;35(suppl 2):839–848. PubMed CrossRef
  29. Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010;363(27):2611–2620. PubMed CrossRef
  30. Reilly S, Planner C, Gask L, et al. Collaborative care approaches for people with severe mental illness. Cochrane Database Syst Rev. 2013;(11):CD009531. PubMed CrossRef
  31. Kilbourne AM, Barbaresso MM, Lai Z, et al. Improving physical health in patients with chronic mental disorders: 12-month results from a randomized controlled collaborative care trial. J Clin Psychiatry. 2017;78(1):129–137. PubMed CrossRef
  32. Bauer MS, McBride L, Williford WO, et al; Cooperative Studies Program 430 Study Team. Collaborative care for bipolar disorder, part I: intervention and implementation in a randomized effectiveness trial. Psychiatr Serv. 2006;57(7):927–936. PubMed CrossRef
  33. Gertner AK, Grove LR, Swietek KE, et al. Enhanced primary care for people with serious mental illness: a propensity weighted cohort study. J Clin Psychiatry. 2023;84(3):22m14496. PubMed CrossRef
  34. Goldstone LW, DiPaula BA, Werremeyer A, et al. The role of board-certified psychiatric pharmacists in expanding access to care and improving patient outcomes. Psychiatr Serv. 2021;72(7):794–801. PubMed CrossRef
  35. Eaves S, Gonzalvo J, Hamm JA, et al. The evolving role of the pharmacist for individuals with serious mental illness. J Am Pharm Assoc (Wash DC). 2020;60(5S):S11–S14. PubMed CrossRef
  36. Heisler M, Hofer TP, Schmittdiel JA, et al. Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial. Circulation. 2012;125(23):2863–2872. PubMed CrossRef
  37. Ridout KK, Ridout SJ, Alavi M, et al. Evaluating implementation and outcomes of the achieving depression and anxiety patient-centered treatment collaborative care program in a large, integrated health care system: a mixed methods observational study protocol. Perm J. 2022;26(4):39–48. PubMed CrossRef
  38. Conway SJ, Kumar P, Nothelle S. Evolution of the care manager: redefining best practices in the COVID-19 era. Popul Health Manag. 2022;25(1):8–10. PubMed CrossRef
  39. Iturralde E, Fazzolari L, Shia M, et al. Closing the care gap for people with severe and persistent mental illness: collaborative care, telehealth, and clinical pharmacy. NEJM Catal. 2022;3(5):CAT.21.0417. PubMed CrossRef
  40. Gordon N. Similarity of adult Kaiser Permanente members to the adult population in Kaiser Permanente’s Northern California service area: comparisons based on the 2017/2018 cycle of the California Health Interview Survey. Oakland, CA: Kaiser Permanente Northern California Division of Research; 2020. Accessed July 14, 2022. https://memberhealthsurvey.kaiser.org/Documents/compare_kp_ncal_chis2017-18.pdf
  41. Ogrinc G, Davies L, Goodman D, et al. Squire 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. Am J Crit Care. 2015;24(6):466–473. PubMed CrossRef
  42. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3–12. PubMed CrossRef
  43. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7-8):1280–1288. PubMed CrossRef
  44. National Committee for Quality Assurance. Diabetes and cardiovascular disease screening and monitoring for people with schizophrenia or bipolar disorder (SSD, SMD, SMC). Accessed October 31, 2022. https://www.ncqa.org/hedis/measures/diabetes-and-cardiovascular-disease-screening-and-monitoring-for-people-with-schizophrenia-or-bipolar-disorder/
  45. Firth J, Siddiqi N, Koyanagi A, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6(8):675–712. PubMed CrossRef
  46. Hackman AL, Goldberg RW, Brown CH, et al. Use of emergency department services for somatic reasons by people with serious mental illness. Psychiatr Serv. 2006;57(4):563–566. PubMed CrossRef
  47. Merrick EL, Perloff J, Tompkins CP. Emergency department utilization patterns for Medicare beneficiaries with serious mental disorders. Psychiatr Serv. 2010;61(6):628–631. PubMed CrossRef
  48. Laraia BA, Karter AJ, Warton EM, et al. Place matters: neighborhood deprivation and cardiometabolic risk factors in the Diabetes Study of Northern California (DISTANCE). Soc Sci Med. 2012;74(7):1082–1090. PubMed CrossRef
  49. Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234–1240. PubMed CrossRef
  50. Cook TD, Campbell DT, Shadish W. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Vol 1195. Houghton Mifflin; 2002.
  51. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121–130. PubMed CrossRef
  52. Little RJ, Rubin DB. Statistical Analysis With Missing Data. Vol. 793. John Wiley & Sons; 2019.
  53. Freedman DA. On the so-called “Huber sandwich estimator” and “robust standard errors.” Am Stat. 2006;60(4):299–302. CrossRef
  54. Thomas L, Li F, Pencina M. Using propensity score methods to create target populations in observational clinical research. JAMA. 2020;323(5):466–467. PubMed CrossRef
  55. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512–522. PubMed CrossRef
  56. Guertin JR, Rahme E, Dormuth CR, et al. Head to head comparison of the propensity score and the high-dimensional propensity score matching methods. BMC Med Res Methodol. 2016;16(1):22. PubMed CrossRef
  57. Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020;323(23):2417–2418. PubMed CrossRef
  58. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. PubMed CrossRef
  59. Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol. 2019;188(1):250–257. PubMed
  60. Reed M, Huang J, Graetz I, et al. Treatment and follow-up care associated with patient-scheduled primary care telemedicine and in-person visits in a large integrated health system. JAMA Netw Open. 2021;4(11):e2132793. PubMed CrossRef
  61. Iturralde E, Weisner CM, Adams SR, et al. Patterns of health care use 5 years after an intervention linking patients in addiction treatment with a primary care practitioner. JAMA Netw Open. 2022;5(11):e2241338. PubMed CrossRef
  62. Ridout KK, Alavi M, Ridout SJ, et al. Changes in diagnostic and demographic characteristics of patients seeking mental health care during the early COVID-19 pandemic in a large, community-based health care system. J Clin Psychiatry. 2021;82(2):20m13685. PubMed CrossRef
  63. Firth J, Cotter J, Torous J, et al. Mobile phone ownership and endorsement of “mHealth” among people with psychosis: a meta-analysis of cross-sectional studies. Schizophr Bull. 2016;42(2):448–455. PubMed CrossRef
  64. Robotham D, Satkunanathan S, Doughty L, et al. Do we still have a digital divide in mental health? a five-year survey follow-up. J Med Internet Res. 2016;18(11):e309. PubMed CrossRef
  65. Bauer R, Glenn T, Strejilevich S, et al. Internet use by older adults with bipolar disorder: international survey results. Int J Bipolar Disord. 2018;6(1):20. PubMed CrossRef
  66. Berry N, Lobban F, Emsley R, et al. Acceptability of interventions delivered online and through mobile phones for people who experience severe mental health problems: a systematic review. J Med Internet Res. 2016;18(5):e121. PubMed CrossRef
  67. Blanco C, Wall MM, Olfson M. Implications of telepsychiatry for cost, quality, and equity of mental health care. JAMA Psychiatry. 2022;79(12):1147–1148. PubMed CrossRef